Takeda to initiate large scale dengue vaccine trial in Asia and Latin America
06-Apr-17, ET Healthworld
Japan's Takeda Pharmaceutical said it had completed enrolment for a 20,000-subject dengue vaccine trial, the largest clinical study in its history, signalling the global ambitions of its vaccine business.
%20ET%20Healthworld.jpg "Takeda to initiate large scale dengue vaccine trial in Asia and Latin America (c) ET Healthworld")
Image: ET Healthworld
Japan's largest drugmaker has taken a decision to become more international under its French CEO Christophe Weber, who took over in 2015.
The international dengue study will test the experimental vaccine on 20,100 children and adolescents in eight countries in Latin America and Asia. Initial results are expected in 2018.
Sanofi already has a dengue vaccine on the market, Dengvaxia, but the product is not perfect